Study protocol for a phase II randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke

Introduction Stroke is a common cause of epilepsy that may be mediated via glutamate dysregulation. There is currently no evidence to support the use of antiseizure medications as primary prevention against poststroke epilepsy. Perampanel has a unique antiglutamatergic mechanism of action and may ha...

Full description

Bibliographic Details
Main Authors: Patrick Kwan, Zhibin Chen, Terence J O'Brien, Udaya Seneviratne, Geoffrey Cloud, John-Paul Nicolo, Bradford Moffat, David K Wright, Benjamin Sinclair, Rebecca Glarin, Andrew Neal
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/5/e043488.full